Hepatocellular cancer

  • Tiziana is developing Milciclib for the treatment of HCC, the worlds most common primary cancer  and a leading cause of cancer-related death in the United States.
  • Between 2003 to 2012, rates of new liver cancer cases went up 38% according to the Centers for Disease Control and Prevention.
  • Most HCC patients present with advanced disease and do not benefit from transplantation, surgical resection, or locoregional therapies.
  • Sorafenib (standard of care) and Lenvatinib are approved in the United States and EU as first line-treatment for advanced HCC patients.
  • The primary risk factor for HCC is hepatic cirrhosis.

The following graphic represents the progression from a healthy liver to NAFLD, NASH, cirrhosis and HCC.

NAFLD NASH progression